The Food and Drug Administration (FDA) has approved a new generic version of Diovan (Novartis) that does not contain N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA), 2 potentially carcinogenic impurities identified in several recalled valsartan products.
PDL BioPharma has announced the availability of an authorized generic version of Tekturna (aliskiren hemifumarate; Noden Pharma).
Eli Lilly announced plans to launch an authorized generic version of Humalog (insulin lispro) 100 Units/mL at a 50% lower list price.
An authorized generic of Flector Patch (diclofenac epolamine topical patch) has been made available by Teva Pharmaceuticals for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Generic versions of Suboxone (buprenorphine and naloxone; Indivior) Sublingual Film have been made available by Sandoz and Alvogen.
Nexus announced that the Food and Drug Administration (FDA) has approved Dicyclomine HCl Injection, 20mg/2mL, the generic version of Aptalis Pharma’s Bentyl Injection.
Wixela Inhub (fluticasone propionate and salmeterol inhalation powder), the first substitutable generic of Advair Diskus (GlaxoSmithKline), has been made available by Mylan
Alyq should not be used with concomitant organic nitrates or guanylate cyclase (GC) stimulators (eg, riociguat), and in patients with a known serious hypersensitivity to tadalafil.
Mylan plans to make Wixela Inhub available in 3 strengths: 100mcg/50mcg, 250mcg/50mcg, and 500mcg/50mcg.
This is currently the only liquid formulation of this agent available in the US.
Please login or register first to view this content.
